Strikingly, in cGAMP-treated tumours, 37% of ECs were positive for the apoptosis marker cleaved caspase3 (C.Casp3), while C.Casp3 positivity was observed in <2% of ECs in PBS-treated tumours. Here, CASP3 is linked to neoplasm.